机构：[1]Head of Ophthalmology: Catholic University of Asunción School of Medicine, Asunción, Paraguay.[2]Consultant Vitreo-Retinal Surgeon: Retina Research Unit, National Eye, Colombo, Sri Lanka.[3]Ophthalmologist: Tongren Hospital, Beijing, China.首都医科大学附属同仁医院[4]Deputy Director: Vision and Eye Research Institute, Faculty of Health, Medicine and Social Care, Anglia Ruskin University, UK.[5]Professor: Medical Research Foundation, Sankara Nethralaya & Indian Institute of Technology, Madras, Chennai, India.[6]Consultant Ophthalmologist, Tennent Institute of Ophthalmology, Gartnavel Hospital, Glasgow, Scotland.
出处：
ISSN：
摘要：
A major barrier to the treatment
of macular diseases is the cost of
anti-VEGF drugs. As the patents on
these drugs expire, lower cost biosimilar
drugs have become available. According
to the World Health Organization, a
biosimilar is a bio-therapeutic product
which is similar in terms of quality, safety
and efficacy to an already licensed (or
reference) bio-therapeutic product.1
They are similar, not equal; their active
ingredients are not identical to those of
the reference product. The adoption of
a biosimilar varies between countries
due to factors such as regulatory approval,
market acceptance, and health care policies.1–2
The following short reports from Latin America,
Sri Lanka, and China give an insight into how the
introduction of biosimilars has affected practice in
these regions.
语种：
外文
PubmedID：
第一作者：
第一作者机构：[1]Head of Ophthalmology: Catholic University of Asunción School of Medicine, Asunción, Paraguay.
推荐引用方式(GB/T 7714)：
Cano Miriam,Dhanapala Mangala,Kang Mengtian,et al.Biosimilars for anti-VEGF treatment of macular diseases: country and region reports[J].Community Eye Health.2025,37(125):22-23.
APA：
Cano Miriam,Dhanapala Mangala,Kang Mengtian,Piyasena Mapa Prabhath,Raman Rajiv&Yorston David.(2025).Biosimilars for anti-VEGF treatment of macular diseases: country and region reports.Community Eye Health,37,(125)
MLA：
Cano Miriam,et al."Biosimilars for anti-VEGF treatment of macular diseases: country and region reports".Community Eye Health 37..125(2025):22-23
